Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | MPI | P34949 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | TDP2 | O95551 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937553 | 1.00 | KDM4E (0.61) | KDM4EL3MBTL1MPIMAPTMEN1 | |
| SCHEMBL2170981 | 0.84 | KMT2A (0.59) | KDM4EL3MBTL1MPIMAPTMEN1 | |
| SCHEMBL196848 | 0.83 | KMT2A (0.68) | KDM4EL3MBTL1MPIMAPTMEN1 | |
| SCHEMBL19990071 | 0.83 | KDM4E (0.70) | KDM4EL3MBTL1MPIMAPTMEN1 | |
| SCHEMBL18280047 | 0.77 | SLC40A1 (0.48) | KDM4EL3MBTL1MPIMAPTMEN1 | |
| SCHEMBL24876033 | 0.76 | KDM4E (0.61) | KDM4EL3MBTL1MPIMAPTMEN1 | |
| SCHEMBL3559305 | 0.76 | KDM4E (0.61) | KDM4EL3MBTL1MPIMAPTMEN1 | |
| SCHEMBL12566070 | 0.76 | KDM4E (0.55) | KDM4EL3MBTL1MPIMAPTMEN1 | |
| SCHEMBL2208961 | 0.76 | KDM4E (0.61) | KDM4EL3MBTL1MPIMAPTMEN1 | |
| SCHEMBL2557719 | 0.76 | L3MBTL1 (0.61) | KDM4EL3MBTL1MPIMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503471-B2 | Triazatricycle compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12486273-B2 | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12421229-B2 | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4058452-B1 | HYDROPYRAZINO[1,2-B]ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025011623-A1 | CYANOQUINOLINE-TARGETING PROTEIN DEGRADATION MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-12157746-B2 | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-114728959-B | Hydropyrazino [1,2-b ] isoquinoline compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114728976-B | Hydrogen-1H-pyrrolo [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-114599652-B | Hydropyrazino [1,2-d ] [1,4] diazepine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20080045510-A1 | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| EP-1888559-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | Wyeth a Corporation of the State of Delaware (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070299083-A1 | 6-Methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007146115-A2 | 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE HYDROCHLORIC ACID SALTS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146072-A2 | PROCESS FOR SYNTHESIZING PIPERAZINE-PIPERIDINE COMPOUNDS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146202-A2 | SUCCINATE SALTS OF 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| WO-2006135839-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | WYETH (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HRH3, HRH4, HRH2 | KDM4E 1890/4885L3MBTL1 4575/4885MPI 4147/4885 |
| US-12421229-B2 | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease | TLR7, TLR9, TLR1 | KDM4E 3039/4885L3MBTL1 4179/4885MPI 3035/4885 |
| US-20070299083-A1 | 6-Methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts | HTR5A, HTR2C, HTR1A | KDM4E 3120/4885L3MBTL1 4858/4885MPI 1815/4885 |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | HTR5A, HTR2C, HTR1D | KDM4E 907/4885L3MBTL1 4495/4885MPI 3230/4885 |
| US-12157746-B2 | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | HLA-DRB1, SSB, REN | KDM4E 1925/4885L3MBTL1 3225/4885MPI 3087/4885 |
| US-12486273-B2 | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease | AQP1, HRH2, HRH1 | KDM4E 3726/4885L3MBTL1 4043/4885MPI 2522/4885 |
| US-20080045510-A1 | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof | HTR5A, SUCNR1, HTR2C | KDM4E 1347/4885L3MBTL1 4841/4885MPI 2132/4885 |
| US-12503471-B2 | Triazatricycle compounds for the treatment of autoimmune disease | SSB, HLA-DRB1, PKD1 | KDM4E 2024/4885L3MBTL1 3692/4885MPI 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.